Aether Industries Ltd
Incorporated in 2013, Aether Industries Limited is a manufacturer of specialty chemicals. The company is sole Indian manufacturer for chemicals such as 4-(2-Methoxyethyl) Phenol (4MEP), and 3-Methoxy-2-Methylbenzoyl Chloride (MMBC), Thiophene-2-Ethanol (T2E), Ortho Tolyl Benzo Nitrile (OTBN), N-Octyl-D-Glucamine, Delta-Valerolactone, and Bifenthrin Alcohol.[1]
- Market Cap ₹ 19,918 Cr.
- Current Price ₹ 1,501
- High / Low ₹ 1,538 / 723
- Stock P/E 88.0
- Book Value ₹ 185
- Dividend Yield 0.00 %
- ROCE 11.9 %
- ROE 9.66 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 8.11 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 7.91% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 590 | 651 | 598 | 839 | 1,160 | |
| 422 | 465 | 466 | 598 | 796 | |
| Operating Profit | 168 | 186 | 132 | 241 | 364 |
| OPM % | 28% | 29% | 22% | 29% | 31% |
| 7 | 17 | 25 | 30 | 12 | |
| Interest | 13 | 5 | 9 | 13 | 18 |
| Depreciation | 15 | 23 | 40 | 45 | 66 |
| Profit before tax | 146 | 174 | 110 | 213 | 291 |
| Tax % | 26% | 25% | 25% | 26% | 25% |
| 109 | 130 | 82 | 158 | 219 | |
| EPS in Rs | 9.67 | 10.47 | 6.22 | 11.95 | 16.54 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 21% |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| TTM: | 35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 12% |
| 1 Year: | 93% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 8% |
| Last Year: | 10% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 113 | 125 | 133 | 133 | 133 |
| Reserves | 274 | 1,120 | 1,931 | 2,093 | 2,323 |
| 291 | 16 | 183 | 200 | 458 | |
| 92 | 120 | 154 | 218 | 288 | |
| Total Liabilities | 770 | 1,380 | 2,401 | 2,644 | 3,201 |
| 257 | 646 | 853 | 1,117 | 1,506 | |
| CWIP | 58 | 37 | 232 | 363 | 506 |
| Investments | 17 | 1 | 0 | 0 | 0 |
| 438 | 695 | 1,315 | 1,163 | 1,189 | |
| Total Assets | 770 | 1,380 | 2,401 | 2,644 | 3,201 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -5 | -7 | -16 | 100 | 142 | |
| -151 | -348 | -424 | -418 | -619 | |
| 169 | 439 | 894 | 2 | 244 | |
| Net Cash Flow | 12 | 84 | 453 | -316 | -233 |
| Free Cash Flow | -157 | -363 | -444 | -352 | -390 |
| CFO/OP | 17% | 14% | 1% | 57% | 54% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 101 | 145 | 142 | 126 | 123 |
| Inventory Days | 221 | 301 | 411 | 356 | 326 |
| Days Payable | 95 | 99 | 124 | 114 | 120 |
| Cash Conversion Cycle | 227 | 348 | 429 | 367 | 330 |
| Working Capital Days | 82 | 268 | 279 | 238 | 160 |
| ROCE % | 18% | 7% | 10% | 12% |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| CRAMS Revenue as % of Total Revenue % |
|
||||||||
| R&D as % of Revenue % |
|||||||||
| R&D Expenditure INR MM |
|||||||||
| Capacity Utilization - Manufacturing Facility 2 (Site 2) % |
|||||||||
| Products in Portfolio count |
|||||||||
| Total Customers count |
|||||||||
| Capacity Utilization - Manufacturing Facility 3 (Site 3) % |
|||||||||
| Capacity Utilization - Manufacturing Facility 4 (Site 4) % |
|||||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Grant Of Employee Stock Options
8 Jul - Granted 1,77,996 stock options at Rs. 1,200 each under ESOS 2021 on July 8, 2026.
-
Intimation For The Commencement Of Operation At Site 5
26 Jun - Commercial operations began at Site 5, GIDC Panoli, on June 26, 2026, supporting capacity and revenue growth.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
24 Jun - In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended from time to time, we herewith submit the …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
24 Jun - Aether Industries scheduled investor meeting on June 29 and analyst meeting on June 30, 2026.
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
15 Jun - In accordance with Reg. 30 of the SEBI (LODR) regulations, 2015, we herewith inform about allotment of 3,677 shares under AIL ESOS 2021, as annexed.
Annual reports
Concalls
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
Jul 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Jan 2025TranscriptAI SummaryPPT
-
Oct 2024Transcript PPT REC
-
Jul 2024TranscriptPPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Jul 2023Transcript PPT
-
Jun 2023Transcript PPT
-
May 2023TranscriptAI SummaryPPT
-
Jan 2023Transcript PPT
-
Jan 2023TranscriptAI SummaryPPT
-
Nov 2022Transcript PPT
-
Jul 2022Transcript PPT
-
Jun 2022Transcript PPT
Business Segments[1] [2]
a) Contract / Exclusive Manufacturing (46% in FY26 vs 31% in FY25): [3]
The company produces products for its customers under contractual supply agreements that can be either short-term or long-term, and may be exclusive or non-exclusive in nature. It has entered into long-term take-or-pay contracts with global clients such as Baker Hughes, SEQENS, and Saudi Aramco.